Labcorp To Acquire Select BioRefernce Assets From OPKO In Deal Worth Up To $872 Million; Stock Up
Labcorp (LH) will acquire select BioReference Health assets from OPKO Health (OPK) for up to $872M. The deal includes BioReference's clinical testing businesses and the 4Kscore Test. Labcorp expects $250M in first-year revenue from the acquisition, pending regulatory approval. OPK's stock rose 3.79% on the news.
How this was made
The 30-second read
Why it matters
The disclosed consideration ($722M cash plus up to $150M contingent) and the stated first-year revenue expectation ($250M) create a near-term repricing catalyst for both companies, subject to regulatory approvals and closing conditions.
Market read
A sizable diagnostics asset acquisition with a proprietary FDA-approved test and a revenue-linked earnout is likely to drive deal-spread and valuation adjustments for both LH and OPK.
What to watch
Key sensitivities are the regulatory approval timeline, the nature of “select assets” retained by OPKO, and how the earnout is calculated versus real-world test utilization and reimbursement dynamics.
Background
Labcorp and OPKO agreed on a transaction where Labcorp buys select BioReference Health laboratory testing businesses and the FDA-approved 4Kscore blood test from OPKO’s wholly owned subsidiary.
Ticker impact
Labcorp agreed to acquire BioReference Health assets from OPKO for $722M cash plus up to $150M contingent on 4Kscore revenue.
Likely upward bias as investors price in expanded diagnostics revenue and a meaningful, but contingent, earnout tied to 4Kscore performance.
The article discloses a large cash component, a defined earnout mechanism, and first-year revenue expectations, which are direct inputs to valuation and deal-risk assessment.
OPKO will sell select BioReference Health assets to Labcorp for $722M cash, with potential additional $150M tied to future 4Kscore revenue.
Mixed reaction risk, with upside from monetization and downside from losing revenue-generating assets and execution/regulatory uncertainty.
The article provides deal consideration and strategic rationale, but does not quantify OPKO’s post-transaction earnings impact beyond the earnout linkage.
Market effects
Could be read as continued consolidation in US specialty diagnostics and lab services, with emphasis on proprietary oncology testing platforms.
Primarily US-focused expansion via more than 80 patient service centers and nationwide access to 4Kscore.
Limited direct global read-through, but may influence investor sentiment toward diagnostic services M&A and specialty test commercialization models.
Counterpoint
Investors may discount the first-year revenue forecast if regulatory approval or integration delays push closing out, or if 4Kscore adoption underperforms the earnout assumptions.
Key entities
- companyLabcorp
US laboratory services and diagnostics provider acquiring BioReference Health assets and the 4Kscore test.
- companyOPKO Health
Biopharmaceutical and diagnostics company selling select BioReference Health assets to streamline operations.
- companyBioReference Health
OPKO subsidiary whose laboratory testing businesses and 4Kscore test are being acquired by Labcorp.
- product4Kscore Test
FDA-approved blood test used to assess likelihood of aggressive prostate cancer prior to biopsy decisions.
